Chiba University in Japan recently announced the results of a new study that found that the severity of COVID-19 is highly correlated with the concentration of myosin light chain 9 (Myl9) protein in the blood. The findings could help hospitals determine which patient groups should be prioritized for admission and discharge, and thereby reduce the burden on the healthcare system.
A research team led by Chiba University Hospital announced on Aug. 1 that they published a study in the Proceedings of the National Academy of Sciences at the end of July that found the higher the concentration of Myl9 in the plasma of patients with COVID-19, the more severe the patient’s condition, and the longer the hospitalization time.
